Regulatory, payer and operational reasoning are never carried through together.
Feasibility is treated as aspiration. Country and site choices ignore actual protocol burden.
Endpoint logic never becomes site reality. The protocol lives in a strategy deck, not in the field.
No single accountability structure catches drift before it becomes redesign or data-integrity risk.
Find the assumptions most likely to destroy decision value.
Convert criticism into a workable evidence and operating architecture.
Create explicit decisions, ownership, interfaces and escalation rules.
Protect signal integrity, quality, timing and interpretability through database lock.
The model scales from one senior expert to a coordinated clinical-trial delivery system. The more complex the work, the more capabilities must be conducted as one accountable whole.
Hourly / on demand. Senior input for a specific question, review or decision, with no reserved capacity.
Fixed or capped fee. A clearly defined output with agreed scope, interfaces, deliverable and budget.
Monthly retainer / reserved capacity. Ongoing CMO-level ownership and senior medical leadership with agreed availability, decision rights and continuity.
Project / milestone budget. Coordinated clinical-trial delivery across functions, vendors and countries, with defined milestones, governance and accountable execution.
Combined commercial structure. Two or more engagement models can be combined when the work requires both continuity and defined project outputs.
MB & Partners owns the clinical architecture, including design risk, endpoints, feasibility logic, country strategy, governance and evidence requirements. Verum provides the accountable execution spine across project management, medical oversight, quality, startup, biometrics, safety and sponsor-facing accountability. NECTAR activates qualified local delivery behind Global Clinical Trial Execution where regional depth adds speed and realism.
Enrollment, startup, quality, vendors, data flow and decisions due.
Trajectory, leading indicators, uncertainty and corrective actions.
Evidence progress, capital exposure and continue, adapt or stop.
Safety, signal integrity, critical path or decision-gate threats.
The right governance model starts with the decisions the evidence must support.
